| Net product sales | 2.97B |
| Collaborative agreements and other revenue | 14.2M |
| Royalty revenue | |
| Total revenue | 2.98B |
| Cost of goods sold (excluding amortization of acquired intangible assets) | |
| Research and development | 1.65B |
| Selling, general and administrative | 698M |
| Amortization of acquired intangible assets | |
| Acquisition related (gains) charges and restructuring, net | 25M |
| Total costs and expenses | 2.57B |
| Operating income | 411.5M |
| Interest and investment income, net | 7.3M |
| Equity in (gains) losses of affiliated companies | |
| Interest expense | -127.8M |
| Other income, net | -34.2M |
| Income before income taxes | 256.8M |
| Income tax provision | 85.4M |
| Net income | 171.4M |
| Less: Net loss attributable to non-controlling interest | |
| Net income attributable to Celgene | |
| Basic | 0.22 |
| Diluted | 0.21 |
| Basic | 775.8M |
| Diluted | 801.5M |